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Obesity has become a worldwide epidemic, and its prevalence has been projected to grow by 40% in the next decade.
This increasing prevalence has implications for the risk of diabetes, cardiovascular disease, and also for chronic
kidney disease (CKD). A high body mass index is one of the strongest risk factors for new-onset CKD. In individuals
affected by obesity, a compensatory hyperﬁltration occurs to meet the heightened metabolic demands of the increased
body weight. The increase in intraglomerular pressure can damage the kidneys and raise the risk of developing CKD
in the long-term. The incidence of obesity-related glomerulopathy has increased tenfold in recent years. Obesity has
also been shown to be a risk factor for nephrolithiasis, and for a number of malignancies including kidney cancer.
This year the World Kidney Day promotes education on the harmful consequences of obesity and its association with
kidney disease, advocating healthy lifestyle, and health policy measures that makes preventive behaviors an
affordable option.
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Introduction
In 2014, over 600 million adults worldwide, 18 years and older, were obese. Obesity is a
potent risk factor for the development of kidney disease. It increases the risk of developing
major risk factors for chronic kidney disease (CKD), like diabetes and hypertension, and it
has a direct impact on the development of CKD and end-stage renal disease (ESRD). In
individuals affected by obesity, a (likely) compensatory mechanism of hyperﬁltration occurs
to meet the heightened metabolic demands of the increased body weight. The increase in
intraglomerular pressure can damage the kidney structure and raise the risk of developing
CKD in the long-term.
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The good news is that obesity, as well as the related CKD, are largely preventable.
Education and awareness of the risks of obesity and a healthy lifestyle, including proper
nutrition and exercise, can dramatically help in preventing obesity and kidney disease. This
article reviews the association of obesity with kidney disease on the occasion of the 2017
World Kidney Day.
Epidemiology of Obesity in Adults and Children
Over the last three decades, the prevalence of overweight and obese adults (BMI ≥25 kg/m2)
worldwide has increased substantially (25). In the USA, the age-adjusted prevalence of
obesity in 2013–2014 was 35% among men and 40.4% among women (24). The problem of
obesity also affects children. In the USA in 2011–2014, the prevalence of obesity was 17%
and extreme obesity 5.8% among youth 2–19 years of age. The rise in obesity prevalence is
also a worldwide concern (9, 61), as it is projected to grow by 40% across the globe in the
next decade. Low- and middle-income countries are now showing evidence of transitioning
from normal weight to overweight and obesity as parts of Europe and the USA performed a
decade ago (78). This increasing prevalence of obesity has implications for cardiovascular
disease (CVD) and also for CKD. A high body mass index (BMI) is one of the strongest risk
factors for new-onset CKD (22, 83).
Deﬁnitions of obesity are most often based on BMI [i.e., weight (kilograms) divided by
the square of his or her height (meters)]. A BMI between 18.5 and 25 kg/m2 is considered by
the World Health Organization (WHO) to be normal weight, a BMI between 25 and 30 kg/m2
as overweight, and a BMI of >30 kg/m2 as obese. Although BMI is easy to calculate, it is a
poor estimate of fat mass distribution, as muscular individuals or those with more subcuta-
neous fat may have a BMI as high as individuals with larger intraabdominal (visceral) fat. The
latter type of high BMI is associated with substantially higher risk of metabolic and CVD.
Alternative parameters to more accurately capture visceral fat include waist circumference
(WC) and a waist–hip ratio (WHR) of >102 cm and 0.9, respectively, for men and >88 cm
and >0.8, respectively, for women. WHR has been shown to be superior to BMI for the
correct classiﬁcation of obesity in CKD.
Association of Obesity with CKD and Other Renal Complications
Numerous population-based studies have shown an association between measures of obesity
and both the development and the progression of CKD (Table I). Higher BMI is associated
with the presence (63) and development (10, 26, 47) of proteinuria in individuals without
kidney disease. Furthermore, in numerous large population-based studies, higher BMI
appears associated with the presence (20, 63) and development of low estimated glomerular
ﬁltration rate (GFR) (26, 31, 47), with more rapid loss of estimated GFR over time (54), and
with the incidence of ESRD (35, 36, 58, 84). Elevated BMI levels, class II obesity and above,
have been associated with more rapid progression of CKD in patients with pre-existing CKD
(53). A few studies examining the association of abdominal obesity using WHR or WC with
CKD, describe an association between higher girth and albuminuria (81), decreased GFR
(63) or incident ESRD (46) independent of BMI level.
Higher visceral adipose tissue measured by computed tomography has been associated
with a higher prevalence of albuminuria in men (27). The observation of a BMI-independent
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association between abdominal obesity and poorer renal outcomes is also described in
relationship with mortality in patients with ESRD (65) and kidney transplantation (45) and
suggests a direct role of visceral adiposity. In general, the associations between obesity and
poorer renal outcomes persist even after adjustments for possible mediators of obesity’s
cardiovascular and metabolic effects, such as high blood pressure and diabetes mellitus,
suggesting that obesity may affect kidney function through mechanisms in part unrelated to
these complications (vide infra).
The deleterious effect of obesity on the kidneys extends to other complications such as
nephrolithiasis and kidney malignancies. Higher BMI is associated with an increased
prevalence (72) and incidence (14, 80) of nephrolithiasis. Furthermore, weight gain over
time and higher baseline WC were also associated with higher incidence of nephrolithiasis
(80). Obesity is associated with various types of malignancies, particularly cancers of the
kidneys. In a population-based study of 5.24 million individuals from the UK, a 5 kg/m2
higher BMI was associated with a 25% higher risk of kidney cancers, with 10% of all kidney
cancers attributable to excess weight (5). Another large analysis examining the global burden
of obesity on malignancies estimated that 17% and 26% of all kidney cancers in men and
women, respectively, were attributable to excess weight (2). The association between obesity
and kidney cancers was consistent in both men and women, and across populations from
different parts of the world in a meta-analysis that included data from 221 studies (of which
17 examined kidney cancers) (68). Among the cancers examined in this meta-analysis,
kidney cancers had the third highest risk associated with obesity (relative risk per 5 kg/m2
higher BMI: 1.24, 95% CI: 1.20–1.28, p< 0.0001) (68).
Mechanisms of Action Underlying the Renal Effects of Obesity
Obesity results in complex metabolic abnormalities which have wide-ranging effects on
diseases affecting the kidneys. The exact mechanisms whereby obesity may worsen or cause
CKD remain unclear. The fact that most obese individuals never develop CKD, and the
distinction of up to as many as 25% of obese individuals as “metabolically healthy” suggests
that increased weight alone is not sufﬁcient to induce kidney damage (6). Some of the
deleterious renal consequences of obesity may be mediated by downstream comorbid
conditions such as diabetes mellitus or hypertension, but there are also effects of adiposity
which could impact the kidneys directly, induced by the endocrine activity of the adipose
tissue via production of (among others) adiponectin (73), leptin (87), and resistin (21)
(Fig. 1). These include the development of inﬂammation (3), oxidative stress (30), abnormal
lipid metabolism (70), activation of the rennin–angiotensin–aldosterone system (71), and
increased production of insulin and insulin resistance (62, 67).
These various effects result in speciﬁc pathologic changes in the kidneys (41), which
could underlie the higher risk of CKD seen in observational studies. These include ectopic
lipid accumulation (19) and increased deposition of renal sinus fat (28, 33), the development
of glomerular hypertension and increased glomerular permeability caused by hyperﬁltration-
related glomerular ﬁltration barrier injury (43), and ultimately the development of glomer-
ulomegaly (82), and focal or segmental glomerulosclerosis (41) (Fig. 2). The incidence of the
so-called obesity-related glomerulopathy (ORG) has increased tenfold between 1986 and
2000 (41). Importantly, ORG often presents along with pathophysiologic processes related to
other conditions or advanced age, conspiring to result in more accentuated kidney damage in
patients with high blood pressure (69) or in the elderly (54, 62).
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Obesity is associated with a number of risk factors contributing to the higher incidence
and prevalence of nephrolithiasis. Higher body weight is associated with lower urine pH (55)
and increased urinary oxalate (51), uric acid, sodium and phosphate excretion (74). Diets
richer in protein and sodium may lead to a more acidic urine and decrease in urinary citrate,
also contributing to kidney stone risk. The insulin resistance characteristic of obesity may
also predispose to nephrolithiasis (79) through its impact on tubular Na-H exchanger (42) and
ammoniagenesis (13), and the promotion of an acidic milieu (17). Complicating the picture is
the fact that some weight loss therapies result in a worsening, rather than an improvement in
the risk of kidney stone formation; for example, gastric surgery can lead to a substantial
increase in enteral oxalate absorption and enhanced risk of nephrolithiasis (75).
The mechanisms behind the increased risk of kidney cancers observed in obese
individuals are less well characterized. Insulin resistance, and the consequent chronic
Fig. 1. Putative mechanisms of action whereby
obesity causes chronic kidney disease
Fig. 2. Obesity-related perihilar
focal segmental
glomerulosclerosis on a
background of glomerulomegaly.
Periodic acid–Schiff stain, original
magniﬁcation 400×. Courtesy of
Dr. Patrick D. Walker, MD,
Arkana Laboratories, Little Rock,
AR, USA
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hyperinsulinemia and increased production of insulin-like growth factor 1 and numerous
complex secondary humoral effects may exert stimulating effects on the growth of various
types of tumor cells (8). More recently, the endocrine functions of adipose tissue (16), its
effects on immunity (49), and the generation of an inﬂammatory milieu with complex effects
on cancers (32, 52) have emerged as additional explanations.
Obesity in Patients with Advanced Kidney Disease: The Need for a Nuanced Approach
Considering the above evidence about the overwhelmingly deleterious effects of obesity on
various disease processes, it is seemingly counterintuitive that obesity has been consistently
associated with lower mortality rates in patients with advanced CKD (44, 53) and ESRD
(4, 40). Similar “paradoxical” associations have also been described in other populations,
such as in patients with congestive heart failure (15), chronic obstructive pulmonary disease
(85), rheumatoid arthritis (23), and even in old individuals (39). It is possible that the
seemingly protective effect of a high BMI is the result of the imperfection of BMI as a
measure of obesity, as it does not differentiate the effects of adiposity from those of higher
non-adipose tissue. Indeed, studies that separated the effects of a higher WC from those of
higher BMI showed a reversal of the inverse association with mortality (45, 65). Higher
muscle mass has also been shown to explain at least some of the positive effects attributed to
elevated BMI (4, 59). However, there is also evidence to suggest that higher adiposity, in
particular subcutaneous (non-visceral) fat, may also be associated with better outcomes in
ESRD patients (40). Such beneﬁts may indeed be present in patients who have very low
short-term life expectancy, such as most ESRD patients (18). Indeed, some studies that
examined the association of BMI with time-dependent survival in ESRD have shown a
marked contrast between protective short-term effects versus deleterious long-term effects of
higher BMI (76). There are several putative short-term beneﬁts that higher body mass could
portend, in particular to sicker individuals. These include a beneﬁt from the better nutritional
status typically seen in obese individuals, and which provides better protein and energy
reserves in the face of acute illness, and a higher muscle mass with enhanced antioxidant
capacity (4) and lower circulating actin and higher plasma gelsolin levels (50), which are
associated with better outcomes. Other hypothetically beneﬁcial characteristics of obesity
include a more stable hemodynamic status with mitigation of stress responses and heightened
sympathetic and rennin–angiotensin activity (34); increased production of adiponectines (77)
and soluble tumor necrosis factor α receptors (57) by adipose tissue neutralizing the adverse
effects of tumor necrosis factor α; enhanced binding of circulating endotoxins (66) by the
characteristically higher cholesterol levels seen in obesity; and sequestration of uremic toxins
by adipose tissue (38).
Potential Interventions for Management of Obesity
Obesity engenders kidney injury via direct mechanisms through deranged synthesis of
various adipose tissue cytokines with nephrotoxic potential, as well as indirectly by triggering
diabetes and hypertension, that is, two conditions that rank among the strongest risk factors
for CKD. Perhaps due to the survival advantage of obesity in CKD, the prevalence of end-
stage kidney disease is on the rise both in the USA (48) and in Europe (64). Strategies for
controlling the obesity-related CKD epidemic at population level and for countering the
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evolution of CKD toward kidney failure in obese patients represent the most tantalizing task
that today’s health planners, health managers, and nephrologists face.
Countering CKD at population level
Calls for public health interventions in the community to prevent and treat CKD at an early
stage have been performed by major renal associations, including the International Society of
Nephrology, International Federation of Kidney Foundation, the European Renal Association
– European Dialysis and Transplant Association and various national societies. In the USA,
Healthy People 2020, a program that sets 10-year health targets for health promotion and
prevention goals, focuses on both CKD and obesity. Surveys to detect obese patients,
particularly those with a high risk of CKD (e.g., hypertensive and/or diabetic obese people)
and those receiving suboptimal care to inform these patients of the potential risk of CKD they
are exposed to, is the ﬁrst step toward developing public health interventions. Acquiring
evidence that current interventions to reduce CKD risk in the obese are efﬁcacious and
deployable is an urgent priority to set goals and means for risk modiﬁcation. Appropriate
documentation of existing knowledge distilling the risk and the beneﬁts of primary and
secondary prevention interventions in obese people, and new trials in this population to ﬁll
knowledge gaps (see below) are needed. Finally, surveillance programs that monitor progress
on the detection of at-risk individuals and the effectiveness of prevention programs being
deployed (88) constitute the third, fundamental element for establishing efﬁcacious CKD
prevention plans at population level.
A successful surveillance system for CKD has already been implemented in some places
such as the United Kingdom (UK) (60). A campaign to disseminate and apply K-DOQI CKD
guidelines in primary care within the UK National Health Service was launched. This
progressively increased the adoption of K-DOQI guidelines and, also thanks to speciﬁc
incentives for UK general physicians to detect CKD, led to an impressive improvement in the
detection and care of CKD, that is, better control of hypertension and increased use of
angiotensin-converting enzyme (ACE) and angiotensin receptor blockers (60). This system
may serve as a platform to improve the prevention of obesity-related CKD. Campaigns
aiming at reducing the obesity burden are now at center stage worldwide and are strongly
recommended by the WHO and it is expected that these campaigns will reduce the incidence
of obesity-related complications, including CKD. However obesity-related goals in obese
CKD patients remain vaguely formulated, largely because of the paucity of high-level
evidence intervention studies to modify obesity in CKD patients (7).
Prevention of CKD progression in obese people with CKD
Observational studies in metabolically healthy obese subjects show that the obese phenotype
unassociated with metabolic abnormalities per se predicts a higher risk of incident CKD (12)
suggesting that obesity per se may engender renal dysfunction and kidney damage even
without diabetes or hypertension (vide supra). In overweight or obese diabetic patients, a
lifestyle intervention including caloric restriction and increased physical activity compared
with a standard follow-up based on education and support to sustain diabetes treatment
reduced the risk of incident CKD by 30%, although it did not affect the incidence of
cardiovascular events (86). Such a protective effect was partly due to reductions in body
weight, HbA1c, and systolic blood pressure. No safety concerns regarding kidney-related
adverse events were seen (86). In a recent meta-analysis collating experimental studies in
obese CKD patients, interventions aimed at reducing body weight showed coherent
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reductions in blood pressure, glomerular hyper-ﬁltration, and proteinuria (7). A thorough post
hoc analysis of the Ramipril Efﬁcacy In Nephropathy (REIN) study showed that the nephron-
protective effect of ACE inhibition in proteinuric CKD patients was maximal in obese CKD
patients, but minimal in CKD patients with normal or low BMI (56). Of note, bariatric
surgical intervention has been suggested for selected CKD and ESRD patients including
dialysis patients who are waitlisted for kidney transplantation (11, 29, 37).
Globally, these experimental ﬁndings provide a proof of concept for the usefulness of
weight reduction and ACE inhibition interventions in the treatment of CKD in the obese.
Studies showing a survival beneﬁt of increased BMI in CKD patients, however, remain to be
explained (1). These ﬁndings limit our ability to make strong recommendations about
the usefulness and the safety of weight reduction among individuals with more advanced
stages of CKD. Lifestyle recommendations to reduce body weight in obese people at risk of
CKD and in those with early CKD appear justiﬁed, particularly recommendations for the
control of diabetes and hypertension. As the independent effect of obesity control on the
incidence and progression of CKD is difﬁcult to disentangle from the effects of hypertension
and type 2 diabetes, recommendation of weight loss in the minority of metabolically healthy,
non-hypertensive obese patients remains unwarranted. These considerations suggest that a
therapeutic approach to overweight and obesity in patients with advanced CKD or other
signiﬁcant comorbid conditions has to be pursued carefully, with proper considerations of the
expected beneﬁts and potential complications of weight loss over the life span of the
individual patient.
Conclusions
The worldwide epidemic of obesity affects the Earth’s population in many ways. Diseases of
the kidneys, including CKD, nephrolithiasis and kidney cancers are among the more
insidious effects of obesity, but which nonetheless have wide-ranging deleterious conse-
quences, ultimately leading to signiﬁcant excess morbidity and mortality and excess costs to
individuals and the entire society. Population-wide interventions to control obesity could
have beneﬁcial effects in preventing the development or delaying the progression of CKD. It
is incumbent upon the entire healthcare community to devise long-ranging strategies toward
improving the understanding of the links between obesity and kidney diseases, and to
determine optimal strategies to stem the tide. The 2017 World Kidney Day is an important
opportunity to increase education and awareness to that end.
REFERENCES
1. Ahmadi SF, Zahmatkesh G, Ahmadi E, Streja E, Rhee CM, Gillen DL, De Nicola L, Minutolo R, Ricardo AC,
Kovesdy CP, Kalantar-Zadeh K: Association of body mass index with clinical outcomes in non-
dialysis-dependent chronic kidney disease: a systematic review and meta-analysis. Cardiorenal. Med. 6,
37–49 (2015)
2. Arnold M, Pandeya N, Byrnes G, Renehan AG, Stevens GA, Ezzati M, Ferlay J, Miranda JJ, Romieu I, Dikshit
R, Forman D, Soerjomataram I: Global burden of cancer attributable to high body-mass index in 2012: a
population-based study. Lancet Oncol. 16, 36–46 (2015)
3. Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, Capeau J, Feve B: Recent advances in the
relationship between obesity, inﬂammation, and insulin resistance. Eur. Cytokine Netw. 17, 4–12 (2006)
4. Beddhu S, Pappas LM, Ramkumar N, Samore M: Effects of body size and body composition on survival in
hemodialysis patients. J. Am. Soc. Nephrol. 14, 2366–2372 (2003)
10 Kovesdy et al.
Physiology International (Acta Physiologica Hungarica) 104, 2017
5. Bhaskaran K, Douglas I, Forbes H, dos-Santos-Silva I, Leon DA, Smeeth L: Body-mass index and risk of
22 speciﬁc cancers: a population-based cohort study of 5.24 million UK adults. Lancet 384, 755–765 (2014)
6. Bluher M: The distinction of metabolically ‘healthy’ from ‘unhealthy’ obese individuals. Curr. Opin. Lipidol. 21,
38–43 (2010)
7. Bolignano D, Zoccali C: Effects of weight loss on renal function in obese CKD patients: a systematic review.
Nephrol. Dial Transplant. 28(Suppl. 4), iv82–iv98 (2013)
8. Calle EE, Kaaks R: Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat.
Rev. Cancer 4, 579–591 (2004)
9. Cattaneo A, Monasta L, Stamatakis E, Lioret S, Castetbon K, Frenken F, Manios Y, Moschonis G, Savva S,
Zaborskis A, Rito AI, Nanu M, Vignerova J, Caroli M, Ludvigsson J, Koch FS, Serra-Majem L, Szponar L, van
Lenthe F, Brug J: Overweight and obesity in infants and pre-school children in the European Union: a review of
existing data. Obes. Rev. 11, 389–398 (2010)
10. Chang A, Van Horn L, Jacobs DR Jr, Liu K, Muntner P, Newsome B, Shoham DA, Durazo-Arvizu R,
Bibbins-Domingo K, Reis J, Kramer H: Lifestyle-related factors, obesity, and incident microalbuminuria: the
CARDIA (Coronary Artery Risk Development in Young Adults) study. Am. J. Kidney Dis. 62, 267–275 (2013)
11. Chang AR, Chen Y, Still C, Wood GC, Kirchner HL, Lewis M, Kramer H, Hartle JE, Carey D, Appel LJ, Grams
ME: Bariatric surgery is associated with improvement in kidney outcomes. Kidney Int. 90, 164–171 (2016)
12. Chang Y, Ryu S, Choi Y, Zhang Y, Cho J, Kwon MJ, Hyun YY, Lee KB, Kim H, Jung HS, Yun KE, Ahn J,
Rampal S, Zhao D, Suh BS, Chung EC, Shin H, Pastor-Barriuso R, Guallar E: Metabolically healthy obesity and
development of chronic kidney disease: a cohort study. Ann. Intern. Med. 164, 305–312 (2016)
13. Chobanian MC, Hammerman MR: Insulin stimulates ammoniagenesis in canine renal proximal tubular
segments. Am. J. Physiol. 253, F1171–F1177 (1987)
14. Curhan GC, Willett WC, Rimm EB, Speizer FE, Stampfer MJ: Body size and risk of kidney stones. J. Am. Soc.
Nephrol. 9, 1645–1652 (1998)
15. Curtis JP, Selter JG, Wang Y, Rathore SS, Jovin IS, Jadbabaie F, Kosiborod M, Portnay EL, Sokol SI, Bader F,
Krumholz HM: The obesity paradox: body mass index and outcomes in patients with heart failure. Arch. Intern.
Med. 165, 55–61 (2005)
16. Dalamaga M, Diakopoulos KN, Mantzoros CS: The role of adiponectin in cancer: a review of current evidence.
Endocr. Rev. 33, 547–594 (2012)
17. Daudon M, Lacour B, Jungers P: Inﬂuence of body size on urinary stone composition in men and women. Urol.
Res. 34, 193–199 (2006)
18. Dekker FW, de Mutsert R, van Dijk PC, Zoccali C, Jager KJ: Survival analysis: time-dependent effects and time-
varying risk factors. Kidney Int. 74, 994–997 (2008)
19. de Vries AP, Ruggenenti P, Ruan XZ, Praga M, Cruzado JM, Bajema IM, D’Agati VD, Lamb HJ, Pongrac BD,
Hojs R, Abbate M, Rodriquez R, Mogensen CE, Porrini E: Fatty kidney: emerging role of ectopic lipid in
obesity-related renal disease. Lancet Diabetes Endocrinol. 2, 417–426 (2014)
20. Ejerblad E, Fored CM, Lindblad P, Fryzek J, McLaughlin JK, Nyren O: Obesity and risk for chronic renal
failure. J. Am. Soc. Nephrol. 17, 1695–1702 (2006)
21. Ellington AA, Malik AR, Klee GG, Turner ST, Rule AD, Mosley TH Jr, Kullo IJ: Association of plasma resistin
with glomerular ﬁltration rate and albuminuria in hypertensive adults. Hypertension 50, 708–714 (2007)
22. Elsayed EF, Sarnak MJ, Tighiouart H, Grifﬁth JL, Kurth T, Salem DN, Levey AS, Weiner DE: Waist-to-hip
ratio, body mass index, and subsequent kidney disease and death. Am. J. Kidney Dis. 52, 29–38 (2008)
23. Escalante A, Haas RW, del Rinco´n I: Paradoxical effect of body mass index on survival in rheumatoid arthritis:
role of comorbidity and systemic inﬂammation. Arch. Intern. Med. 165, 1624–1629 (2005)
24. Flegal KM, Kruszon-Moran D, Carroll MD, Fryar CD, Ogden CL: Trends in obesity among adults in the United
States, 2005 to 2014. JAMA 315, 2284–2291 (2016)
25. Forouzanfar MH, Alexander L, Anderson HR, Bachman VF, Biryukov S, Brauer M, Burnett R, Casey D, Coates
MM, Cohen A, Delwiche K, Estep K, Frostad JJ, Astha KC, Kyu HH, Moradi-Lakeh M, Ng M, Slepak EL,
Thomas BA, Wagner J, Aasvang GM, Abbafati C, Abbasoglu OA, Abd-Allah F, Abera SF, Aboyans V,
Abraham B, Abraham JP, Abubakar I, Abu-Rmeileh NM, Aburto TC, Achoki T, Adelekan A, Adofo K, Adou
AK, Adsuar JC, Afshin A, Agardh EE, Al Khabouri MJ, Al Lami FH, Alam SS, Alasfoor D, Albittar MI,
Alegretti MA, Aleman AV, Alemu ZA, Alfonso-Cristancho R, Alhabib S, Ali R, Ali MK, Alla F, Allebeck P,
Allen PJ, Alsharif U, Alvarez E, Alvis-Guzman N, Amankwaa AA, Amare AT, Ameh EA, Ameli O, Amini H,
AmmarW, Anderson BO, Antonio CA, Anwari P, Argeseanu CS, Arnlov J, Arsenijevic VS, Artaman A, Asghar
RJ, Assadi R, Atkins LS, Atkinson C, Avila MA, Awuah B, Badawi A, Bahit MC, Bakfalouni T, Balakrishnan
K, Balalla S, Balu RK, Banerjee A, Barber RM, Barker-Collo SL, Barquera S, Barregard L, Barrero LH,
Obesity and kidney disease 11
Physiology International (Acta Physiologica Hungarica) 104, 2017
Barrientos-Gutierrez T, Basto-Abreu AC, Basu A, Basu S, Basulaiman MO, Batis RC, Beardsley J, Bedi N,
Bekele T, Bell ML, Benjet C, Bennett DA, Benzian H, Bernabe E, Beyene TJ, Bhala N, Bhalla A, Bhutta ZA,
Bikbov B, Bin Abdulhak AA, Blore JD, Blyth FM, Bohensky MA, Bora BB, Borges G, Bornstein NM, Bose D,
Boufous S, Bourne RR, Brainin M, Brazinova A, Breitborde NJ, Brenner H, Briggs AD, Broday DM,
Brooks PM, Bruce NG, Brugha TS, Brunekreef B, Buchbinder R, Bui LN, Bukhman G, Bulloch AG,
Burch M, Burney PG, Campos-Nonato IR, Campuzano JC, Cantoral AJ, Caravanos J, Cardenas R,
Cardis E, Carpenter DO, Caso V, Castaneda-Orjuela CA, Castro RE, Catala-Lopez F, Cavalleri F,
Cavlin A, Chadha VK, Chang JC, Charlson FJ, Chen H, Chen W, Chen Z, Chiang PP, Chimed-Ochir O,
Chowdhury R, Christophi CA, Chuang TW, Chugh SS, Cirillo M, Classen TK, Colistro V, Colomar M,
Colquhoun SM, Contreras AG, Cooper C, Cooperrider K, Cooper LT, Coresh J, Courville KJ, Criqui MH,
Cuevas-Nasu L, Damsere-Derry J, Danawi H, Dandona L, Dandona R, Dargan PI, Davis A, Davitoiu DV,
Dayama A, de Castro EF, De la Cruz-Go´ngora V, De Leo D, de Lima G, Degenhardt L, del Pozo-Cruz B,
Dellavalle RP, Deribe K, Derrett S, Des Jarlais DC, Dessalegn M, deVeber GA, Devries KM, Dharmaratne SD,
Dherani MK, Dicker D, Ding EL, Dokova K, Dorsey ER, Driscoll TR, Duan L, Durrani AM, Ebel BE,
Ellenbogen RG, Elshrek YM, Endres M, Ermakov SP, Erskine HE, Eshrati B, Esteghamati A, Fahimi S,
Faraon EJ, Farzadfar F, Fay DF, Feigin VL, Feigl AB, Fereshtehnejad SM, Ferrari AJ, Ferri CP, Flaxman AD,
Fleming TD, Foigt N, Foreman KJ, Paleo UF, Franklin RC, Gabbe B, Gafﬁkin L, Gakidou E, Gamkrelidze A,
Gankpe FG, Gansevoort RT, Garcia-Guerra FA, Gasana E, Geleijnse JM, Gessner BD, Gething P, Gibney KB,
Gillum RF, Ginawi IA, GiroudM, Giussani G, Goenka S, Goginashvili K, Gomez DH, Gona P, Gonzalez de CT,
Gonzalez-Castell D, Gotay CC, Goto A, Gouda HN, Guerrant RL, Gugnani HC, Guillemin F, Gunnell D,
Gupta R, Gupta R, Gutierrez RA: Global, regional, and national comparative risk assessment of 79 behavioural,
environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a
systematic analysis for the Global Burden of Disease Study 2013. Lancet 386, 2287–2323 (2015)
26. Foster MC, Hwang SJ, Larson MG, Lichtman JH, Parikh NI, Vasan RS, Levy D, Fox CS: Overweight, obesity,
and the development of stage 3 CKD: the Framingham Heart Study. Am. J. Kidney Dis. 52, 39–48 (2008)
27. Foster MC, Hwang SJ, Massaro JM, Hoffmann U, DeBoer IH, Robins SJ, Vasan RS, Fox CS: Association of
subcutaneous and visceral adiposity with albuminuria: the Framingham Heart Study. Obesity (Silver Spring) 19,
1284–1289 (2011)
28. Foster MC, Hwang SJ, Porter SA, Massaro JM, Hoffmann U, Fox CS: Fatty kidney, hypertension, and chronic
kidney disease: the Framingham Heart Study. Hypertension 58, 784–790 (2011)
29. Friedman AN, Wolfe B: Is bariatric surgery an effective treatment for type II diabetic kidney disease? Clin. J.
Am. Soc. Nephrol. 11, 528–535 (2016)
30. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M,
Matsuda M, Shimomura I: Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin.
Invest. 114, 1752–1761 (2004)
31. Gelber RP, Kurth T, Kausz AT, Manson JE, Buring JE, Levey AS, Gaziano JM: Association between body mass
index and CKD in apparently healthy men. Am. J. Kidney Dis. 46, 871–880 (2005)
32. Grivennikov SI, Greten FR, Karin M: Immunity, inﬂammation, and cancer. Cell 140, 883–899 (2010)
33. Henegar JR, Bigler SA, Henegar LK, Tyagi SC, Hall JE: Functional and structural changes in the kidney in the
early stages of obesity. J. Am. Soc. Nephrol. 12, 1211–1217 (2001)
34. Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Woo MA, Tillisch JH: The relationship between
obesity and mortality in patients with heart failure. J. Am. Coll. Cardiol. 38, 789–795 (2001)
35. Hsu C, McCulloch C, Iribarren C, Darbinian J, Go A: Body mass index and risk for end-stage renal disease. Ann.
Intern. Med. 144, 21–28 (2006)
36. Iseki K, Ikemiya Y, Kinjo K, Inoue T, Iseki C, Takishita S: Body mass index and the risk of development of
end-stage renal disease in a screened cohort. Kidney Int. 65, 1870–1876 (2004)
37. Jamal MH, Corcelles R, Daigle CR, Rogula T, Kroh M, Schauer PR, Brethauer SA: Safety and effectiveness of
bariatric surgery in dialysis patients and kidney transplantation candidates. Surg. Obes. Relat. Dis. 11, 419–423
(2015)
38. Jandacek RJ, Anderson N, Liu M, Zheng S, Yang Q, Tso P: Effects of yo-yo diet, caloric restriction, and olestra on
tissue distribution of hexachlorobenzene. Am. J. Physiol. Gastrointest. Liver Physiol. 288, G292–G299 (2005)
39. Kalantar-Zadeh K, Kilpatrick RD, Kuwae N, Wu DY: Reverse epidemiology: a spurious hypothesis or a
hardcore reality? Blood Purif. 23, 57–63 (2005)
40. Kalantar-Zadeh K, Kuwae N, Wu DY, Shantouf RS, Fouque D, Anker SD, Block G, Kopple JD: Associations of
body fat and its changes over time with quality of life and prospective mortality in hemodialysis patients. Am. J.
Clin. Nutr. 83, 202–210 (2006)
12 Kovesdy et al.
Physiology International (Acta Physiologica Hungarica) 104, 2017
41. Kambham N, Markowitz GS, Valeri AM, Lin J, D’Agati VD: Obesity-related glomerulopathy: an emerging
epidemic. Kidney Int. 59, 1498–1509 (2001)
42. Klisic J, Hu MC, Nief V, Reyes L, Fuster D, Moe OW, Ambuhl PM: Insulin activates Na+/H+ exchanger 3:
biphasic response and glucocorticoid dependence. Am. J. Physiol. Renal. Physiol. 283, F532–F539 (2002)
43. Knight SF, Quigley JE, Yuan J, Roy SS, Elmarakby A, Imig JD: Endothelial dysfunction and the development of
renal injury in spontaneously hypertensive rats fed a high-fat diet. Hypertension 51, 352–359 (2008)
44. Kovesdy CP, Anderson JE, Kalantar-Zadeh K: Paradoxical association between body mass index and mortality
in men with CKD not yet on dialysis. Am. J. Kidney Dis. 49, 581–591 (2007)
45. Kovesdy CP, Czira ME, Rudas A, Ujszaszi A, Rosivall L, Novak M, Kalantar-Zadeh K, Molnar MZ, Mucsi I:
Body mass index, waist circumference and mortality in kidney transplant recipients. Am. J. Transplant. 10,
2644–2651 (2010)
46. Kramer H, Gutierrez OM, Judd SE, Muntner P, Warnock DG, Tanner RM, Panwar B, Shoham DA, McClellan
W: Waist circumference, body mass index, and ESRD in the REGARDS (Reasons for Geographic and Racial
Differences in Stroke) study. Am. J. Kidney Dis. 67, 62–69 (2016)
47. Kramer H, Luke A, Bidani A, Cao G, Cooper R, McGee D: Obesity and prevalent and incident CKD: the
hypertension detection and follow-up program. Am. J. Kidney Dis. 46, 587–594 (2005)
48. Kramer HJ, Saranathan A, Luke A, Durazo-Arvizu RA, Guichan C, Hou S, Cooper R: Increasing body mass
index and obesity in the incident ESRD population. J. Am. Soc. Nephrol. 17, 1453–1459 (2006)
49. Lamas O, Marti A, Martinez JA: Obesity and immunocompetence. Eur. J. Clin. Nutr. 56(Suppl. 3), S42–S45
(2002)
50. Lee PS, Sampath K, Karumanchi SA, Tamez H, Bhan I, Isakova T, Gutierrez OM, Wolf M, Chang Y, Stossel
TP, Thadhani R: Plasma gelsolin and circulating actin correlate with hemodialysis mortality. J. Am. Soc.
Nephrol. 20, 1140–1148 (2009)
51. Lemann J Jr, Pleuss JA, Worcester EM, Hornick L, Schrab D, Hoffmann RG: Urinary oxalate excretion
increases with body size and decreases with increasing dietary calcium intake among healthy adults. Kidney Int.
49, 200–208 (1996)
52. Lim C, Savan R: The role of the IL-22/IL-22R1 axis in cancer. Cytokine Growth Factor Rev. 25, 257–271 (2014)
53. Lu JL, Kalantar-Zadeh K, Ma JZ, Quarles LD, Kovesdy CP: Association of body mass index with outcomes in
patients with CKD. J. Am. Soc. Nephrol. 25, 2088–2096 (2014)
54. Lu JL, Molnar MZ, Naseer A, Mikkelsen MK, Kalantar-Zadeh K, Kovesdy CP: Association of age and BMI
with kidney function and mortality: a cohort study. Lancet Diabetes Endocrinol. 3, 704–714 (2015)
55. Maalouf NM, Sakhaee K, Parks JH, Coe FL, Adams-Huet B, Pak CY: Association of urinary pH with body
weight in nephrolithiasis. Kidney Int. 65, 1422–1425 (2004)
56. Mallamaci F, Ruggenenti P, Perna A, Leonardis D, Tripepi R, Tripepi G, Remuzzi G, Zoccali C: ACE inhibition
is renoprotective among obese patients with proteinuria. J. Am. Soc. Nephrol. 22, 1122–1128 (2011)
57. Mohamed-Ali V, Goodrick S, Bulmer K, Holly JM, Yudkin JS, Coppack SW: Production of soluble tumor
necrosis factor receptors by human subcutaneous adipose tissue in vivo. Am. J. Physiol. 277, E971–E975 (1999)
58. Munkhaugen J, Lydersen S, Wideroe TE, Hallan S: Prehypertension, obesity, and risk of kidney disease: 20-year
follow-up of the HUNT I study in Norway. Am. J. Kidney Dis. 54, 638–646 (2009)
59. Noori N, Kopple JD, Kovesdy CP, Feroze U, Sim JJ, Murali SB, Luna A, GomezM, Luna C, Bross R, Nissenson
AR, Kalantar-Zadeh K: Mid-arm muscle circumference and quality of life and survival in maintenance
hemodialysis patients. Clin. J. Am. Soc. Nephrol. 5, 2258–2268 (2010)
60. O’Donoghue DJ, Stevens PE: A decade after the KDOQI CKD/guidelines: a perspective from the United
Kingdom. Am. J. Kidney Dis. 60, 740–742 (2012)
61. Olaya B, Moneta MV, Pez O, Bitfoi A, Carta MG, Eke C, Goelitz D, Keyes KM, Kuijpers R, Lesinskiene S,
Mihova Z, Otten R, Fermanian C, Haro JM, Kovess V: Country-level and individual correlates of overweight
and obesity among primary school children: a cross-sectional study in seven European countries. BMC Public
Health 15, 475 (2015)
62. Oterdoom LH, de Vries AP, Gansevoort RT, de Jong PE, Gans RO, Bakker SJ: Fasting insulin modiﬁes the
relation between age and renal function. Nephrol. Dial. Transplant. 22, 1587–1592 (2007)
63. Pinto-Sietsma SJ, Navis G, Janssen WM, de Zeeuw D, Gans RO, de Jong PE: A central body fat distribution is
related to renal function impairment, even in lean subjects. Am. J. Kidney Dis. 41, 733–741 (2003)
64. Postorino M, Mancini E, D’Arrigo G, Marino C, Vilasi A, Tripepi G, Gallus S, Lugo A, Santoro A, Zoccali C:
Body mass index trend in haemodialysis patients: the shift of nutritional disorders in two Italian regions.
Nephrol. Dial. Transplant. 31, 1699–1705 (2016)
Obesity and kidney disease 13
Physiology International (Acta Physiologica Hungarica) 104, 2017
65. Postorino M, Marino C, Tripepi G, Zoccali C: Abdominal obesity and all-cause and cardiovascular mortality in
end-stage renal disease. J. Am. Coll. Cardiol. 53, 1265–1272 (2009)
66. Rauchhaus M, Coats AJ, Anker SD: The endotoxin-lipoprotein hypothesis. Lancet 356, 930–933 (2000)
67. Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37, 1595–1607 (1988)
68. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M: Body-mass index and incidence of cancer: a
systematic review and meta-analysis of prospective observational studies. Lancet 371, 569–578 (2008)
69. Ribstein J, du Cailar G, Mimran A: Combined renal effects of overweight and hypertension. Hypertension 26,
610–615 (1995)
70. Ruan XZ, Varghese Z, Moorhead JF: An update on the lipid nephrotoxicity hypothesis. Nat. Rev. Nephrol. 5,
713–721 (2009)
71. Ruster C, Wolf G: The role of the renin-angiotensin-aldosterone system in obesity-related renal diseases. Semin.
Nephrol. 33, 44–53 (2013)
72. Scales CD Jr, Smith AC, Hanley JM, Saigal CS: Prevalence of kidney stones in the United States. Eur. Urol. 62,
160–165 (2012)
73. Sharma K: The link between obesity and albuminuria: adiponectin and podocyte dysfunction. Kidney Int. 76,
145–148 (2009)
74. Siener R, Glatz S, Nicolay C, Hesse A: The role of overweight and obesity in calcium oxalate stone formation.
Obes. Res. 12, 106–113 (2004)
75. Sinha MK, Collazo-Clavell ML, Rule A, Milliner DS, Nelson W, Sarr MG, Kumar R, Lieske JC: Hyperoxaluric
nephrolithiasis is a complication of Roux-en-Y gastric bypass surgery. Kidney Int. 72, 100–107 (2007)
76. Snyder JJ, Foley RN, Gilbertson DT, Vonesh EF, Collins AJ: Body size and outcomes on peritoneal dialysis in
the United States. Kidney Int. 64, 1838–1844 (2003)
77. Stenvinkel P, Marchlewska A, Pecoits-Filho R, Heimburger O, Zhang Z, Hoff C, Holmes C, Axelsson J,
Arvidsson S, Schalling M, Barany P, Lindholm B, Nordfors L: Adiponectin in renal disease: relationship to
phenotype and genetic variation in the gene encoding adiponectin. Kidney Int. 65, 274–281 (2004)
78. Subramanian SV, Perkins JM, Ozaltin E, Davey SG: Weight of nations: a socioeconomic analysis of women in
low- to middle-income countries. Am. J. Clin. Nutr. 93, 413–421 (2011)
79. Taylor EN, Stampfer MJ, Curhan GC: Diabetes mellitus and the risk of nephrolithiasis. Kidney Int. 68,
1230–1235 (2005)
80. Taylor EN, Stampfer MJ, Curhan GC: Obesity, weight gain, and the risk of kidney stones. JAMA 293, 455–462
(2005)
81. Thoenes M, Reil JC, Khan BV, Bramlage P, Volpe M, Kirch W, BohmM: Abdominal obesity is associated with
microalbuminuria and an elevated cardiovascular risk proﬁle in patients with hypertension. Vasc. Health Risk
Manag. 5, 577–585 (2009)
82. Tsuboi N, Utsunomiya Y, Kanzaki G, Koike K, Ikegami M, Kawamura T, Hosoya T: Low glomerular density
with glomerulomegaly in obesity-related glomerulopathy. Clin. J. Am. Soc. Nephrol. 7, 735–741 (2012)
83. Tsujimoto T, Sairenchi T, Iso H, Irie F, Yamagishi K, Watanabe H, Tanaka K, Muto T, Ota H: The dose-
response relationship between body mass index and the risk of incident stage ≥3 chronic kidney disease in a
general Japanese population: the Ibaraki Prefectural Health Study (IPHS). J. Epidemiol. 24, 444–451 (2014)
84. Vivante A, Golan E, Tzur D, Leiba A, Tirosh A, Skorecki K, Calderon-Margalit R: Body mass index in 1.2
million adolescents and risk for end-stage renal disease. Arch. Intern. Med. 172, 1644–1650 (2012)
85. Wilson DO, Rogers RM, Wright EC, Anthonisen NR: Body weight in chronic obstructive pulmonary disease.
The National Institutes of Health Intermittent Positive-Pressure Breathing Trial. Am. Rev. Respir. Dis. 139,
1435–1438 (1989)
86. Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, Crow RS, Curtis JM, Egan CM, Espeland MA,
Evans M, Foreyt JP, Ghazarian S, Gregg EW, Harrison B, Hazuda HP, Hill JO, Horton ES, Hubbard VS, Jakicic
JM, Jeffery RW, Johnson KC, Kahn SE, Kitabchi AE, Knowler WC, Lewis CE, Maschak-Carey BJ, Montez MG,
Murillo A, Nathan DM, Patricio J, Peters A, Pi-Sunyer X, Pownall H, Reboussin D, Regensteiner JG, Rickman
AD, Ryan DH, Safford M, Wadden TA, Wagenknecht LE, West DS, Williamson DF, Yanovski SZ: Cardiovas-
cular effects of intensive lifestyle intervention in type 2 diabetes. N. Engl. J. Med. 369, 145–154 (2013)
87. Wolf G, Ziyadeh FN: Leptin and renal ﬁbrosis. Contrib. Nephrol. 151, 175–183 (2006)
88. World Health Organization (2009): 2008–2013 Action Plan for the Global Strategy for the Prevention and
Control of Noncommunicable Diseases. World Health Organization, Geneva.
14 Kovesdy et al.
Physiology International (Acta Physiologica Hungarica) 104, 2017
